Medicinal compositions containing anti-Fas antibody

A composition and antibody technology, applied in the field of new pharmaceutical compositions, can solve problems such as lack of understanding of synergy

Inactive Publication Date: 2005-03-09
SANKYO CO LTD
View PDF14 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] On the other hand, it is known that cA2, a monoclonal antibody against tumor necrosis factor α (TNFα), can improve the therapeutic effect on patients with rheumatoid arthritis by combining it with methotrexate (Carden, The 7th International Symposium on Rheumatology Summary (1998) pp. 12-13), but the synergistic effect of anti-Fas antibodies and methotrexate etc. is completely unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal compositions containing anti-Fas antibody
  • Medicinal compositions containing anti-Fas antibody
  • Medicinal compositions containing anti-Fas antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0142] As the anti-Fas antibody, the anti-human Fas monoclonal antibody HFE7A or CH11 (manufactured by the Institute of Medical Biology, Ltd.) described in European Patent Publication No. 0909816 was used.

[0143] The human lymphocyte cell line HPB-ALL (refer to Morikawa, S., et al. (1978) Int. J. Cancer 21, 166-170) was cultured in RPMI 1640 medium containing 10% FCS (manufactured by Gibco B.R.L.), Cultivate at 37°C in the presence of 5% carbon dioxide for 3 days, and then inject 50 μl (2.5×10 5 cells / 50 μl). Then, 50 µl of RPMI medium containing methotrexate (manufactured by Sigma) and anti-Fas antibody (CH11 or HFE7A, serially diluted 3 times from 0.001 mg / ml) was added to each well, and cultured at 37°C.

[0144] The plate to which CH11 was added as an anti-Fas antibody was directly incubated overnight at 37°C. On the other hand, in the culture plate supplemented with HFE7A, cells were washed with RPMI medium after culturing for 1 hour, and then 100 μl / well of an anti-m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Novel medicinal compositions containing anti-Fas antibody which are useful as preventives or remedies for autoimmune diseases or rheumatoid arthritis. More particularly, medicinal compositions containing as the active ingredients antihuman Fas antibody having an activity of inducing apoptosis and a compound having an antagonism to folic acid or an effect of inhibiting dihydrofolate reductase. By using these medicinal compositions, the content of anti-Fas antibody can be reduced in preventives or remedies for autoimmune diseases or rheumatoid arthritis containing anti-Fas antibody. Thus, the possibility of the appearance of the tolerance in the patient's body due to the expression of an antibody against the anti-Fas antibody, etc., which makes it possible to provide excellent preventives or remedies usable in long-term administration.

Description

technical field [0001] The present invention relates to a novel pharmaceutical composition effective in the prevention or treatment of autoimmune diseases or rheumatoid arthritis. Background technique [0002] Physiological cell death caused by alternation of normal cell generations in organisms is called apoptosis, which is different from necrosis of pathological cell death (refer to Kerr, et a1. (1972) Br.J.Cancer 26 , 239). Programmed cell death is a pre-programmed active cell death process that occurs in certain cells in an organism, and apoptosis is also one of them. The bending of the cell surface, the condensation of nuclear chromatin, and the fragmentation of chromosomal DNA can be characteristically observed in the process of cell apoptosis. [0003] Apoptosis acts during the differentiation of lymphocytes (T cells and B cells) to exclude cells that recognize self-antigens. The cause of autoimmune diseases is considered to be the insufficiency of apoptosis in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/519A61K39/395A61P19/02A61P29/00A61P37/02A61P37/06C07C279/26C07D475/08C07K16/28
CPCA61K39/395A61K2039/505C07K16/2878C07K2317/73C07D475/08C07C279/26A61K39/39533A61P19/02A61P29/00A61P37/02A61P37/06A61K31/00A61K2300/00
Inventor 芹泽伸记市川公久好田宏子
Owner SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap